ArticlePharmaceutical research2026
Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor used in HER2-positive breast cancer (BC). Here, we identified prognostic genes modulated by lapatinib and evaluated whether glucose-functionalized, lapatinib-conjugated silver nanoparticles could enhance its anticancer efficacy.
methodsLapatinib-responsive genes were identified from the GSE38376 dataset and their prognostic associations were assessed using The Cancer Genome Atlas (TCGA). Silver nanoparticles were synthesized by Spirulina-mediated reduction of AgNO₃, functionalized with glucose, and conjugated to lapatinib (Ag@Glu-Lapatinib NP), then characterized by FTIR, XRD, zeta potential, SEM, and TEM. SKBR3 cells were treated with Ag@Glu-Lapatinib NP, Ag NP, or lapatinib and evaluated by MTT, Annexin V/PI apoptosis assay, and RT-qPCR for candidate genes.
resultsTranscriptomic analysis indicated that lapatinib suppresses proliferation-associated genes and enriches apoptosis-related pathways. In TCGA, ECE2 and CDCA5 were overexpressed and associated with poorer outcomes, whereas PDK4 and ALDH1A1 were reduced and linked to favorable prognosis. Ag@Glu-Lapatinib NP formation was confirmed, and the nanoformulation showed higher potency (IC₅₀ = 62 μg/mL at 24 h; 31 μg/mL at 48 h) than free lapatinib (250 μg/mL) or Ag NP (125 μg/mL), with markedly increased apoptosis. RT-qPCR verified significant modulation of ECE2, CDCA5, PDK4, and ALDH1A1 after Ag@Glu-Lapatinib NP treatment.
conclusionConjugating lapatinib to glucose-functionalized silver nanoparticles enhances its activity in HER2-positive BC cells and modulates survival-associated genes. This nano-therapeutic strategy may strengthen the therapeutic potential of lapatinib in breast cancer.
Indexed as
Identifiers
41741910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.